LightOx appoints experienced Non-Executive Directors and closes investment round
Today LightOx Ltd, a North East based company announces the appointment of two new Non-Executive Directors to its board.
Newcastle upon Tyne, UK, 2nd May 2019
Mr Paul Lelieveld and Dr Frans van Dalen have joined the LightOx team and will support the development of new light-activated drugs and fluorescent probes being produced at the company. The two appointments bring a wealth of knowledge in the pharmaceutical development and regulatory pathways as well as the investment community in this area.
Further to this LightOx announces that it has successfully closed its current funding round with Dutch Biopharma specialists Meneldor acting as the lead. The investment will help the commercialisation of LightOx Probes for use in research markets, and the development of the new drugs being developed by the team for Head & Neck, and skin cancers.
Dr Sam Whitehouse, LightOx CEO says
“We are delighted to welcome Paul and Frans to the team. Their wealth of experience will help us to acceler- ate our activities in both commercialising our LightOx Probes to a global customer base, and our develop- ment of new therapeutics which are activated by light. We look forward to a long and productive future with our new NEDs.”
Mr Paul Lelieveld, Non-Executive Director
“We are pleased to announce our investment in LightOx Ltd. We very much look forward to work with the highly experienced management team and together bring multiple LightOx- based medicines to patients in the future.”
Notes to the Editor
Paul’s experience spans more than 25 years in Business & strategy development, management of technology and investments companies; Paul has successfully led investment rounds in several companies and invested for multple funds.
Frans’ experience spans 30 years in the biopharmaceutical field. He has previously held management positions in Strategic Program Development, QA / QP, Project Management, R&D and Regulatory Affairs. With 25 years as one of the partners that build the Synthon Holding; he is an expert in R& D, Regulatory Affairs, manufacturing and commercialization of generic medicines, biosimilars and New Biological Entities.
Meneldor focuses on early stage biotech and pharma companies that develop Biological or Chemical Molecular Entities, that have outstanding technology with strong IP, address significant unmet medical needs and attractive markets. Meneldor offers the unique opportunity to invest alongside specialists, in exciting early stage companies up to and including phase 2 Biotech and Pharma companies. A sector often considered as very risky and highly complex. Meneldor thoroughly studies the science behind her potential portfolio companies. If the science is sound, then all other key aspects; Management, IP, medical need, addressable markets, competition, risk, financial needs, valuation, etc., are assessed. Only if a target company meets our selection criteria, Meneldor will invest and invite her investors to participate.
Meneldor invests in projects which are in preclinical, Phase I or Phase II and in indications with preferably clear well-defined clinical endpoints with a geographic focus in Western Europe.
About LightOx Ltd
LightOx Limited, was founded in 2016 and is based in North East England.
The company develops fluorescent drugs that are capable of targeting selected cell types and killing them on illumination with light. The technology will initially be used to target cancers in the Head & Neck and skindiseases.
LightOx also has a range of fluorescent probes that are available to researchers to use in imaging at the cellular and subcellular levels. The probes enable cell imaging, detection, tracking and tagging of bioactivemolecules. LightOx is also developing equipment for the controlled delivery of light in cell assays for the lifescience markets.
Winner of “BioNow Best Start Up” Award in 2018
Images: Paul & Frans